EAM
IRON icon

Exome Asset Management’s Disc Medicine IRON Stock Holding History

Exome Asset Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$1.27M – 70
2025
Q4 		$1.27M Buy
+16,000
New +$1.35M 0.61% 47

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Exome Asset Management's IRON Position: Q1 2026 in Review

Exome Asset Management sold out of Disc Medicine (IRON) in Q1 2026, closing a stake of 46,743 shares — an estimated $3.71M sold.

Exome Asset Management first reported a position in IRON in Q2 2024 and held it in 7 quarters. The position peaked at $4.38M in Q4 2024. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Exome Asset Management reported no remaining Disc Medicine position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 46,743 Disc Medicine shares in Q1 2026, an estimated $3.71M.
  • Exome Asset Management first reported a position in Disc Medicine in Q2 2024 and held it in 7 quarters.
  • Exome Asset Management's Disc Medicine position peaked at $4.38M in Q4 2024.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.